ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2016
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St slides as oil hovers near $100 on rising Middle East tensions
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Oil nears $100 as fresh Middle East strikes raise supply risks
- How big a risk are rates to the AI boom?
- 3 reasons why S&P 500 may drop up to 10% in the near term: RBC
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Macquarie Upgrades ResMed (RMD) to Neutral
April 28, 2016 7:08 AM EDTMacquarie upgraded ResMed (NYSE: RMD) from Underperform to Neutral.
For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.
Shares of ResMed closed at $56.65 yesterday.
... MorePiper Jaffray Downgrades ResMed (RMD) to Neutral
April 27, 2016 6:37 AM EDTPiper Jaffray downgraded ResMed (NYSE: RMD) from Overweight to Neutral with a price target of $57.00 (from $65.00).
Analyst Matt O'Brien commented, "We are downgrading RMD to Neutral from Overweight and lowering our PT to $57 from $65. The genesis of our downgrade is that we believe headwinds and the lack of near term... More
ResMed (RMD) Misses Q3 EPS by 1c
April 26, 2016 4:14 PM EDTResMed (NYSE: RMD) reported Q3 EPS of $0.68, $0.01 worse than the analyst estimate of $0.69. Revenue for the quarter came in at $453.9 million versus the consensus estimate of $455.88 million.
For earnings history and earnings-related data on ResMed (RMD) click here.
... More